Clinical trials: Grass Pollen Allergy
Rhinitis, Allergic, Seasonal
An Exploratory Study of PQ Grass 27600 SU
PQGrass309 is aimed at exploring the expected average treatment effect of PQ Grass 27600 SU cumulative dose on symptom and medication score in a field setting.
- Trial name
- NCT04687059
- Testing
- PQ Grass
- Where
- 14 sites in United States, Germany
- Volunteers
- 119 people
- Sponsor
- Allergy Therapeutics
Rhinoconjunctivitis
Evaluation of Safety and Efficacy of Specific Immunotherapy With Recombinant Major Allergens of Timothy Grass Pollen Adsorbed Onto Aluminium-hydroxide in Patients With IgE-mediated Allergic Rhinoconjunctivitis +/- Controlled Asthma
Efficacy and Safety from a high-dosed subcutaneous recombinant preparation
- Trial name
- AMETHYST (NCT00671268)
- Testing
- AL0704rP
- Where
- Germany
- Volunteers
- 256 people
- Sponsor
- Allergopharma GmbH & Co. KG
Hay Fever
Clinical Efficacy and Safety of Subcutaneous Immunotherapy With gpASIT+™ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis
This is a randomised, double-blind, placebo-controlled, international, multicentre, confirmatory Phase III study in patients with grass pollen-related allergic rhinoconjunctivitis.
- Trial name
- NCT03724240
- Testing
- gpASIT+TM
- Volunteers
- 624 people
- Sponsor
- ASIT Biotech S.A.
Allergy to Grass Pollen
Biological Standardization of Poa Pratensis Allergen Extract
The objective of this study is to determine the biologic activity of a Poa pratensis allergen extract in histamine equivalent prick (HEP) units, in order to be used as in-house reference preparation (IHRP).
- Trial name
- NCT01430117
- Testing
- Four different concentrations of Poa pratensis allergen extract, positive control and negative control
- Where
- 2 sites in Spain
- Volunteers
- 31 people
- Sponsor
- Laboratorios Leti, S.L.
Allergic Rhinitis, Allergic Rhinoconjunctivitis
Demonstration of a Decongestant Effect of "Coldamaris Akut" Compared to Saline Nasal Spray.
Allergic rhinitis (AR) in its seasonal and perennial form is a common allergic condition. The majority of allergic rhinitis sufferers report nasal (congestion, sneezing, itching and rhinorrhea) and ocular (redness, watery eyes…
- Trial name
- NCT04532762
- Testing
- nasal spray
- Where
- Austria
- Volunteers
- 42 people
- Sponsor
- Marinomed Biotech AG
Allergic Rhinitis Due to Grass Pollen
Determination of Grass Pollen Allergen Concentration Inducing Rhinoconjunctivitis Symptoms in Subjects Allergic to Grass Pollen in ALYATEC Allergen Exposure Chamber
The aim of this study is to determine the optimal concentration of grass pollen allergens inducing rhinoconjunctivitis in subjects allergic to grass pollen in ALYATEC allergen exposure chamber.
- Trial name
- NCT06104293
- Testing
- Grass Pollen Allergen Exposure
- Where
- France
- Volunteers
- 24 people
- Sponsor
- Alyatec
Allergic Rhinitis
OC000459 Dose Finding Study in Hay Fever Sufferers.
The primary objective of this study is to evaluate a range of dose levels for efficacy in the control of symptoms of allergic rhinitis
- Trial name
- NCT00697281
- Testing
- OC000459
- Where
- Austria
- Volunteers
- 120 people
- Sponsor
- Oxagen Ltd
Allergy to Grass Pollen (Secale Cereale)
Biological Standardization of Secale Cereale Allergen Extract
The objective of this study is to determine the biologic activity of a Secale cereale allergen extract in histamine equivalent prick (HEP) units, in order to be used as in-house reference preparation (IHRP).
- Trial name
- NCT01408238
- Testing
- Four different concentrations of Secale cereale allergen extract, positive control and negative control
- Where
- 2 sites in Spain
- Volunteers
- 35 people
- Sponsor
- Laboratorios Leti, S.L.
Allergy, Rhinitis
Efficacy and Safety From a High-dosed Sublingual Grass Pollen Preparation
Efficacy and Safety from a high-dosed sublingual grass pollen preparation
- Conditions
- Allergy, Rhinitis, Conjunctivitis
- Trial name
- ALLEGRA6 (NCT00623701)
- Testing
- Allerslit forte
- Where
- Germany
- Volunteers
- 126 people
- Sponsor
- Allergopharma GmbH & Co. KG
Allergic Rhinoconjunctivitis
Subcutaneous Immunotherapy in Patients Sensitized to Phleum Pratense
Based on EMA (European Medicines Agency) new guidelines on the clinical development of products for immunotherapy for the treatment of allergic disease the aim of this study was to assess safety and tolerability of three…
- Trial name
- NCT01489033
- Testing
- Subcutaneous immunotherapy with Phleum pratense pollen extract
- Where
- Spain
- Volunteers
- 42 people
- Sponsor
- Roxall Medicina España S.A
Type I Hypersensitivity
Different Doses of Tyrosine Adsorbed Grass Pollen Allergoid With Monophosphoryl Lipid A (MPL) in Patients Sensitized to Grass Pollen
Allergen-specific immunotherapy (SIT), the administration of gradually increasing quantities of an allergen extract to an allergic patient, is a curative approach which directly treats the underlying allergic disease.
- Trial name
- NCT00133159
- Testing
- Grass MATAMPL
- Where
- 3 sites in Canada
- Volunteers
- 68 people
- Sponsor
- Allergy Therapeutics
Rhinitis, Conjunctivitis
Efficacy and Safety of Grass-SPIRE Registration Study
The purpose of this study is to evaluate the safety of Grass-SPIRE compared with placebo and to evaluate the treatment effect of Grass-SPIRE on symptoms and use of rescue medication during the grass pollen season
- Trial name
- NCT02795273
- Testing
- Grass-SPIRE
- Where
- 2 sites in United States
- Sponsor
- Circassia Limited
Allergy
Assessment of Grazax® Treatment Compliance
This trial is performed to assess whether the Grazax® treatment compliance can be improved by use of a compliance device (Memozax®).
- Trial name
- NCT00293046
- Testing
- ALK Grass tablet - use of compliance device
- Where
- Austria
- Volunteers
- 500 people
- Sponsor
- ALK-Abelló A/S
Rhinitis, Rhinoconjunctivitis
Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Grass Pollen Allergy
The purpose of the study is to evaluate the more efficient dose for the treatment of rhinitis/rhinoconjunctivitis against grass pollen allergy
- Trial name
- MG56 (NCT02654223)
- Testing
- MG56 Mannosylated 500 subcutaneous, MG56 Mannosylated 1000 subcutaneous, MG56 Mannosylated 3000 subcutaneous
- Where
- 12 sites in Spain
- Volunteers
- 180 people
- Sponsor
- Inmunotek S.L.
Rhinitis, Conjunctivitis
Study on Pharmacodynamic Parameter and Tolerability With Subcutaneous Immunotherapy in Grass Pollen Allergic Patients
The aim of this study is to test the pharmacodynamic equivalence with respect to IgE-blocking factor and to compare the tolerability of two different updosing schedules with ALK-Flex SQ
- Conditions
- Rhinitis, Conjunctivitis, Asthma
- Trial name
- NCT00857779
- Testing
- subcutaneous immunotherapy
- Where
- Germany
- Volunteers
- 473 people
- Sponsor
- ALK-Abelló A/S
Hypersensitivity
Effect of Different Pre-seasonal BM32 Dosings on the Induction of a Protective Immune Response
BM32 is a product for immunotherapy of grass pollen allergies. It consists of 4 different recombinant proteins (BM321, BM322, BM325 and BM326) adsorbed on alhydrogel. This prospective, double-blind.
- Trial name
- NCT02643641
- Testing
- BM32
- Where
- Austria
- Volunteers
- 130 people
- Sponsor
- Biomay AG
Allergic Rhinitis
Effect of a L. Paracasei Strain on Grass Pollen Allergic Rhinitis Subjects
Various studies in animal and humans have shown a potential beneficial effect of probiotics consumption on allergy. However few studies exist that document their efficacy for upper airways allergies such as allergic rhinitis.
- Trial name
- NCT01233154
- Testing
- probiotic
- Where
- Switzerland
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Allergic Rhinitis
An Exploratory Study of the Effects of a Single Dose of QAX576 (an Interleukin-13 Monoclonal Antibody) on Simulated Hayfever
This study will investigate whether a single dose QAX576 (an interleukin-13 monoclonal antibody) gives protection against a model of hayfever
- Trial name
- NCT00584584
- Testing
- QAX576
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 36 people
- Sponsor
- Novartis
Seasonal Allergic Rhinitis
Dose Selection Study of Efficacy and Safety of Different Doses of Grass MATA MPL and Grass MATA Using mEECs™
There is increasing evidence that the effectiveness of allergy immunotherapy to control symptoms of rhinoconjunctivitis is related to the cumulative dose of allergen or allergoid administered during a single regimen of…
- Trial name
- NCT02582073
- Testing
- Grass MATA MPL (0.5ml) 5100SU, Grass MATA MPL (1.0ml) 10200SU, Grass MATA MPL (1.0ml) 18200SU
- Where
- United States
- Volunteers
- 265 people
- Sponsor
- Allergy Therapeutics
Rhinitis, Allergic, Seasonal
Safety Study of MK-3641 and MK-7243 Co-administered in Adult Participants With Ragweed and Grass Pollen Induced Allergic Rhinitis (P08607, MK-3641-006)
The purpose of this study is to assess the safety and tolerability of MK-3641 (short ragweed [Ambrosia artemisiifolia] extract, SCH 039641, RAGWITEK®) sublingual tablets and MK-7243 (Timothy grass [Phleum pratense] extract, SCH…
- Trial name
- NCT02256553
- Testing
- MK-3641 12 Amb a 1-U (short ragweed extract), MK-7243 2800 BAU (Timothy grass extract), Rescue Medication
- Volunteers
- 102 people
- Sponsor
- ALK-Abelló A/S